Triumvira Immunologics announces fast track designation for its first TAC T-Cell therapeutic product candidate: TAC01-CD19

Triumvira

7 November 2019 - Designation confirms significant unmet need remains in DLBCL.

Triumvira Immunologics today announced that the U.S. FDA has granted fast track designation for its novel T-cell therapy product TAC01-CD19 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior systemic therapies. 

A Phase 1/2 study (TACTIC-19) conducted in patients with CD19-positive B-cell malignancies, including DLBCL, is expected to be initiated by the end of 2019.

Read Triumvira press release

Michael Wonder

Posted by:

Michael Wonder